17Q1 Stock Overview
Provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Pharmaron Beijing Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥1.56 |
| 52 Week High | CN¥2.86 |
| 52 Week Low | CN¥0.89 |
| Beta | 0.84 |
| 11 Month Change | -16.13% |
| 3 Month Change | 69.57% |
| 1 Year Change | -24.27% |
| 33 Year Change | -80.39% |
| 5 Year Change | n/a |
| Change since IPO | -28.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| 17Q1 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -6.6% | 3.9% | 0.8% |
| 1Y | -24.3% | 5.4% | 9.1% |
Return vs Industry: 17Q1 underperformed the German Life Sciences industry which returned 3.6% over the past year.
Return vs Market: 17Q1 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 17Q1 volatility | |
|---|---|
| 17Q1 Average Weekly Movement | 16.6% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 17Q1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 17Q1's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 20,342 | Boliang Lou | www.pharmaron.com |
Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. The company offers laboratory chemistry services, including medicinal and synthetic chemistry, chemistry for new modalities, radiolabelling and radiosynthesis, analytical and purification chemistry, DNA-encoded libraries, cheminformatics, and computer-aided drug design; bioscience services, such as structural biology, in vitro biology, DMPK, in vivo pharmacology, and compound management services; chemistry, manufacturing, and controls services. It also provides clinical development services, including integrated radio labelled science, clinical development, and clinical trial recruitment services; safety assessment, integrated drug discovery, and bioanalysis services; and biologics and cell and gene therapy services, comprising biologics laboratory, biologics CDMO, cell and gene therapy laboratory, and gene therapy CDMO services.
Pharmaron Beijing Co., Ltd. Fundamentals Summary
| 17Q1 fundamental statistics | |
|---|---|
| Market cap | €5.72b |
| Earnings (TTM) | €247.94m |
| Revenue (TTM) | €1.55b |
25.4x
P/E Ratio4.1x
P/S RatioIs 17Q1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 17Q1 income statement (TTM) | |
|---|---|
| Revenue | CN¥11.80b |
| Cost of Revenue | CN¥7.77b |
| Gross Profit | CN¥4.02b |
| Other Expenses | CN¥2.14b |
| Earnings | CN¥1.88b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.06 |
| Gross Margin | 34.12% |
| Net Profit Margin | 15.97% |
| Debt/Equity Ratio | 38.7% |
How did 17Q1 perform over the long term?
See historical performance and comparison